ThermoGenesis Holdings (ThermoGenesis Holdings) Debt-to-Equity : -6.33 (As of Dec. 2023)

View and export this data going back to 1987. Start your Free Trial

What is ThermoGenesis Holdings Debt-to-Equity?

ThermoGenesis Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $7.66 Mil. ThermoGenesis Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.90 Mil. ThermoGenesis Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-1.67 Mil. ThermoGenesis Holdings's debt to equity for the quarter that ended in Dec. 2023 was -6.33.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ThermoGenesis Holdings's Debt-to-Equity or its related term are showing as below:

THMO' s Debt-to-Equity Range Over the Past 10 Years
Min: -6.33 Med: 0.73 Max: 14.75
Current: -6.33

During the past 13 years, the highest Debt-to-Equity Ratio of ThermoGenesis Holdings was 14.75. The lowest was -6.33. And the median was 0.73.

THMO's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.21 vs THMO: -6.33

ThermoGenesis Holdings Debt-to-Equity Historical Data

The historical data trend for ThermoGenesis Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ThermoGenesis Holdings Debt-to-Equity Chart

ThermoGenesis Holdings Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

14.75

1.32

2.73

2.41

-6.33

ThermoGenesis Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															2.41	1.70	2.71	1.82	-6.33

Competitive Comparison of ThermoGenesis Holdings's Debt-to-Equity

For the Medical Devices subindustry, ThermoGenesis Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ThermoGenesis Holdings's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ThermoGenesis Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ThermoGenesis Holdings's Debt-to-Equity falls into.

ThermoGenesis Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ThermoGenesis Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.656	+	2.9)	/	-1.667
	=	-6.33

ThermoGenesis Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.656	+	2.9)	/	-1.667
	=	-6.33

ThermoGenesis Holdings (NAS:THMO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

ThermoGenesis Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of ThermoGenesis Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ThermoGenesis Holdings (ThermoGenesis Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (NAS:THMO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

THR:Germany

Address

2711 Citrus Road, Rancho Cordova, CA, USA, 95742

Website

https://www.thermogenesis.com

ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.

Executives

Xiaochun Xu	director	2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Biao Xi	director	C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
James Xu	director	2453 S. ARCHER AVE, SUITE B, CHICAGO IL 60616
Haihong Zhu	director	2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Debra Donaghy	director	C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS RD., RANCHO CORDOVA CA 95742
Boyalife (hong Kong) Ltd	10 percent owner	2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Thomis Joseph	director	MALEIZENSTRAAT 66, HERENT C9 B-3020
Boyalife Asset Holding Ii, Inc.	10 percent owner	2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Boyalife Group, Inc.	10 percent owner	2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Russell M Medford	director	7935 FAWNDALE WAY, ATLANTA GA 30350
Mark Westgate	director	350 CORPORATE BOULEVARD, ROBBINSVILLE NJ 08691
Jeffery Cauble	officer: Principal Accounting Officer	2711 CITRUS CT., RANCHO CORDOVA CA 95742
Vivian H Liu	director
Boyalife Investment Inc.	10 percent owner	2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Mark Bagnall	director	3876 BAY CENTER PLACE, HAYWARD CA 94545